Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anu Gupta

Nephrology Williamsville, NY Medical Doctor

NPI 1215273511 CMS profile 1993228

325 Essjay Rd, Williamsville, NY 14221

Open in the dashboard

General payments

$566

53 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anu Gupta of Williamsville, NY is reported in the CMS Open Payments database as having received $566 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $180 25
2024 General $72 21
2023 General $3 1
2022 General $25 1
2021 General $170 4
2019 General $115 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anu Gupta
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Anu Gupta were reported at $180. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Anu Gupta Nephrology median Middle half National median
2019 $115 $236 $90–$588 $163
2020 $0 $135 $46–$364 $114
2021 $170 $202 $67–$551 $132
2022 $25 $242 $77–$695 $149
2023 $3 $254 $84–$766 $160
2024 $72 $300 $99–$852 $164
2025 $180 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Fresenius USA Marketing, Inc. $140 2 payments
  2. Organon LLC $123 1 payment
  3. Retrophin, Inc. $119 45 payments
  4. AstraZeneca Pharmaceuticals LP $99 1 payment
  5. Myovant Sciences Inc. $71 3 payments
  6. Relypsa, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $233 6 payments
  2. Education $218 46 payments
  3. Consulting Fee $115 1 payment
Products named General payments · program years 2019–2025
  1. Velphoro $140 2 payments
  2. JADA SYSTEM $123 1 payment
  3. LOKELMA $99 1 payment
  4. MYFEMBREE $71 3 payments
  5. Filspari $43 23 payments
  6. KORSUVA $25 1 payment
  7. Veltassa $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

2,145

Median for Nephrology: 954

Drug cost

$94,779

Median for Nephrology: $127,050

Branded share of claims

14.9%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lokelma Sodium Zirconium Cyclosilicate Brand 21 $20,076
Potassium Citrate Er Potassium Citrate Brand 158 $14,580
Sevelamer Carbonate Generic 52 $7,191
Cinacalcet Hcl Generic 15 $6,673
Bumetanide Generic 197 $6,526
Prosol Parenteral Amino Acid 20% No.1 Brand 46 $4,949
Retacrit Epoetin Alfa-Epbx Brand 27 $3,815
Potassium Chloride Generic 86 $3,800
Eplerenone Generic 17 $2,982
Azathioprine Generic 11 $2,643

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$114,131

Medicare's payments for the services billed

Medicare patients

383

Average age 73

Services billed

2,785

208 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 54%
Arthritis 50%
Ischemic heart disease 49%
Heart failure 48%
Atrial fibrillation 36%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record